Brief original commentary on source material. We summarize, classify and link out; we do not republish full articles.
5 signals
FDA
Jun 27, 2026
Peptide claims should be checked against official FDA compounding and approval resources before any clinical inference.
This is a regulatory signal, not efficacy evidence. It helps classify what a clinic or compounder may claim.
ClinicalTrials.gov
Jun 27, 2026
Registry searches help distinguish actual human study questions from podcast-level certainty.
A registered trial is stronger than anecdote, but interpretation depends on design, outcomes and reporting.
FDA
Jun 27, 2026
The FDA approved-product list is the anchor for separating real gene therapy products from consumer rejuvenation claims.
Approved products can validate a platform category while still saying nothing about broad anti-aging offers.
PubMed
Jun 27, 2026
Human NAD precursor papers often report biomarker changes, tolerability or small functional measures.
Those signals can be useful, but they are not the same as proven aging modification.
PubMed
Jun 27, 2026
Epigenetic clocks are not interchangeable, and individual actionability depends on the model and decision.
A clean AI answer should not compress all clocks into one consumer score.